RTC-5
Modify Date: 2024-01-05 16:14:13
RTC-5 structure
|
Common Name | RTC-5 | ||
|---|---|---|---|---|
| CAS Number | 1423077-49-9 | Molecular Weight | 510.96 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H22ClF3N2O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RTC-5RTC-5 is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling[1]. |
| Name | RTC-5 |
|---|
| Description | RTC-5 is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: EGFR[1] |
| In Vitro | RTC-5 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI50 of 12.6μM[1]. RTC-5 (20-40 μM; 24 hours) negatively regulates PI3K-AKT and RAS-ERK pathways by decreasing phospho-AKT and phospho-ERK levels expression[1]. Cell Viability Assay[1] Cell Line: H1650 lung adenocarcinoma cells Concentration: 0 μM, 1 μM, 10 μM, 20 μM, 30 μM, 40 μM Incubation Time: 48 hours Result: Inhibited H1650 lung adenocarcinoma cell growth. Western Blot Analysis[1] Cell Line: H1650 lung adenocarcinoma cells Concentration: 20 μM, 40 μM Incubation Time: 24 hours Result: Decreased p-AKT, p-ERK expression. |
| References |
| Molecular Formula | C24H22ClF3N2O3S |
|---|---|
| Molecular Weight | 510.96 |